Related Experiment Video

Updated: Feb 19, 2026

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.8K

Status of Testing for High-Level Microsatellite Instability/Deficient Mismatch Repair in Colorectal Carcinoma

Stanley R Hamilton1

  • 1Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.

JAMA Oncology
|November 10, 2017
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

7.5K
Quantification of Colonic Stem Cell Mutations
07:53

Quantification of Colonic Stem Cell Mutations

Published on: September 25, 2015

7.1K

Related Experiment Videos

Last Updated: Feb 19, 2026

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.8K
Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

7.5K
Quantification of Colonic Stem Cell Mutations
07:53

Quantification of Colonic Stem Cell Mutations

Published on: September 25, 2015

7.1K

Related Concept Videos

Mismatch Repair01:20

Mismatch Repair

6.7K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.7K
Mismatch Repair01:36

Mismatch Repair

43.9K
Overview
43.9K

Articles linked to this work by shared authors, journal, and citation graph.

ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Associations of Age With Tumor Genomic Characteristics in Relapsed/Refractory Cancers Interrogated With the NCI-MATCH Trial Targeted Gene Panel Assay.

JCO precision oncology·2026

Perspectives From an Expert-Guided Discussion on Maximizing the Research Potential of Small Biopsy Tissue.

JCO precision oncology·2026

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.

JCO precision oncology·2026

Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E.

JCO precision oncology·2026

Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Immunotherapy in Head and Neck Squamous Cell Carcinoma With PD-L1 Combined Positive Score Less Than 1: A Bayesian Meta-Analysis.

JAMA oncology·2026

PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.

JAMA oncology·2026

Management of Soft Tissue and Visceral Leiomyosarcomas.

JAMA oncology·2026

Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial.

JAMA oncology·2026

Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial.

JAMA oncology·2026

Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.

JAMA oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us